Skip to main content
. 2019 Jul 15;6:23. doi: 10.1186/s40580-019-0193-2

Table 3.

Summary of different organic nanomaterials used as drug delivery carrier for anticancer drugs

Nanocarrier Materials Drug Target References
Liposomes Hyaluronic acid–ceramide and egg phosphatidylcholine Doxorubicin Human breast cancer (in vitro/in vivo) [247]
DSPE-PEG2000-Pen, DSPE-PEG2000-Tf 5-Fluorouracil Human glioblastoma (in vitro) [248]
DPPC, MPPC Tamoxifen, imatinib Human breast cancer (in vitro) [97]
DPPC, cholesterol, DSPE-PEG-FA Celastrol and irinotecan Human Breast cancer (in vitro/in vivo) [236]
DSPE-PEG2000-NHS, pHCT74 peptide Doxorubicin Human prostate cancer (in vitro/in vivo) [249]
CHEMS, DOPE, DSPE-PEG2000 Tariquidar and doxorubicin Human ovarian cancer (in vitro) [241]
Egg phosphatidylcholine, DOPE, CHEMS, DSPE-PEG2000 Resveratrol Human glioblastoma (in vitro) [237]
PC, DSPE-PEG2000 Doxorubicin and celecoxib Human skin cancer (in vitro) [250]
Polymeric nanoparticles PLGA [poly(lactic-co-glycolic acid)], PVA [poly(vinyl alcohol)] Abiraterone acetate and docetaxel Human prostate cancer (in vitro) [251]
MPEG-PVA [poly(vinyl alcohol)] Verapamil and doxorubicin Human ovarian cancer (in vitro) [252]
PLGA [poly(lactic-co-glycolic acid)], PVA [poly(vinyl alcohol)] Resveratrol Human prostate cancer (in vitro) [253]
PLA Calcitriol Human breast cancer (in vitro) [254]
TPGS-b-PCL, Pluronic P123 Sorafenib Human liver carcinoma (in vitro/in vivo) [255]
PLGA [poly(lactic-co-glycolic acid)], PEG, chitosan Curcumin Human pancreatic cancer (in vitro) [256]
PLGA [poly(lactic-co-glycolic acid)], DSPE-PEG Docetaxel Human tongue carcinoma (in vitro) [257]
Dendrimers PAMAM, octa-arginine, PEG Paclitaxel Human cervical carcinoma (in vitro) [258]
PAMAM, N-acetylgalactosamine ligand, PEG Doxorubicin Hepatocellular carcinoma (in vivo) [259]
PAMAM, lactobionic acid Sorafenib Human liver cancer (in vitro) [260]
PAMAM, folic acid Baicalin Human cervical cancer (in vitro) [261]
PAMAM, PEG, AS1411-aptamer Camptothecin Human colon adenocarcinoma (in vitro/in vivo) [262]
PAMAM, OEG Methotrexate Human breast cancer (in vitro/in vivo) [263]
h-PAMAM, PEG-SC Doxorubicin Human gastric cancer (in vitro/in vivo) [264]

The table also shows the type of nanomaterial employed as nanocarrier and target site